drug research for fibromyalgia, AS, PSA, RA, SLE

Addtional information on drugs and medications.

Moderators: Mike Bartolatz, kwork

Post Reply
Mike Bartolatz
Posts: 6595
Joined: Fri Feb 06, 2004 9:58 pm

Re: drug research for fibromyalgia, AS, PSA, RA, SLE

Post by Mike Bartolatz »

Efficacy and Safety of Intravenous Secukinumab in Noninfectious Uveitis Requiring Steroid-Sparing Immunosuppressive Therapy.


Ophthalmology. 2015 Jan 29. pii: S0161-6420(14)01224-X. doi: 10.1016/j.ophtha.2014.12.033. [Epub ahead of print]
Efficacy and Safety of Intravenous Secukinumab in Noninfectious Uveitis Requiring Steroid-Sparing Immunosuppressive Therapy.
Letko E1, Yeh S2, Foster CS3, Pleyer U4, Brigell M5, Grosskreutz CL5; AIN457A2208 Study Group.
Author information

Abstract
PURPOSE:
Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibited promising activity in a proof-of-concept study when administered in intravenous (IV) doses to patients with active, chronic, noninfectious uveitis. This study compared the efficacy and safety of different IV and subcutaneous (SC) doses of secukinumab in patients with noninfectious uveitis.
DESIGN:
Multicenter, randomized, double-masked, dose-ranging, phase 2 clinical trial.
PARTICIPANTS:
Thirty-seven patients with active noninfectious intermediate uveitis, posterior uveitis, or panuveitis who required corticosteroid-sparing immunosuppressive therapy.
METHODS:
Patients were randomized to secukinumab 300 mg SC every 2 weeks for 4 doses, secukinumab 10 mg/kg IV every 2 weeks for 4 doses, or secukinumab 30 mg/kg IV every 4 weeks for 2 doses. Intravenous or SC saline was administered to maintain masking. Efficacy was assessed on day 57 (2-4 weeks after last dose).
MAIN OUTCOME MEASURES:
Percentage of patients with treatment response, defined as (1) at least a 2-grade reduction in vitreous haze score or trace or absent vitreous haze in the study eye without an increase in corticosteroid dose and without uveitis worsening or (2) reduction in corticosteroid dosages to prespecified levels without uveitis worsening. Percentage of patients with remission, defined as anterior chamber cell and vitreous haze scores of 0 or 0.5+ in both eyes without corticosteroid therapy or uveitis worsening.
RESULTS:
Secukinumab 30 mg/kg IV and 10 mg/kg IV, compared with the 300 mg SC dose, produced higher responder rates (72.7% and 61.5% vs. 33.3%, respectively) and remission rates (27.3% and 38.5% vs. 16.7%, respectively). Statistical and clinical superiority for the 30 mg/kg IV dose compared with the 300 mg SC dose was established in a Bayesian probability model. Other measures, including time to response onset, change in visual acuity, and change in vitreous haze score, showed numeric trends favoring IV dosing. Secukinumab, administered in IV or SC formulations, appeared safe and was well tolerated.
CONCLUSIONS:
Intravenous secukinumab was effective and well tolerated in noninfectious uveitis requiring systemic corticosteroid-sparing immunosuppressive therapy. Greater activity with IV dosing suggests that patients may not receive sufficient drug with SC administration. High-dose IV secukinumab may be necessary to deliver secukinumab in therapeutic concentrations.
Copyright © 2015 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
PMID: 25638011 [PubMed - as supplied by publisher]
Mike Bartolatz
Moderator
lexxaus
Posts: 1
Joined: Fri Jun 17, 2016 4:53 pm

Re: drug research for fibromyalgia, AS, PSA, RA, SLE

Post by lexxaus »

very interesting things
Boroboy
Posts: 77
Joined: Wed Oct 22, 2008 5:52 pm

Re: drug research for fibromyalgia, AS, PSA, RA, SLE

Post by Boroboy »

The above biological treatment is now licenced for A.S patients (2016), within the U.K. I'm hoping to try it soon, as I also have A.S. Works in a slightly different way to the anti tnf treatments. Also called Consentyx.
Well found Mike & hope your keeping well.
Post Reply